Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses
EGFR inhibitors used in oncology therapy modify the keratinocyte differentiation processes, impairing proper skin barrier formation and leading to cutaneous adverse drug reactions. To uncover the molecular signatures associated with cutaneous adverse drug reactions, we applied phosphoproteomic and t...
Saved in:
Main Authors: | Thomas Ondet (Author), Pierre-François Roux (Author), Mario Monshouwer (Author), Georgios N. Stamatas (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
by: Tory Starzyk, MA, et al.
Published: (2022) -
Epidermal Growth Factor Induces Vasoconstriction Through the Phosphatidylinositol 3-Kinase-Mediated Mitogen-Activated Protein Kinase Pathway in Hypertensive Rats
by: Kim Junghwan, et al.
Published: (2006) -
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
by: Wennan Zhao, et al.
Published: (2017) -
The Role of Phosphatidylinositol-3-Kinase and AMP-Activated Kinase in the Rapid Estrogenic Attenuation of Cannabinoid-Induced Changes in Energy Homeostasis
by: Edward J. Wagner, et al.
Published: (2011) -
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
by: Elizabeth A Nelson, et al.
Published: (2017)